Home > Result Summaries: Compounds > ropinirole > Result Summary for 101468/053

Result Summary for 101468/053

Result Summary

Protocol ID:	101468/053
Clinical Study ID:	SKF101468/053
Official Title:	A Double-blind, Bromocriptine Controlled, Multicentre Study of Ropinirole at a Flexible Oral Dose of 0.25-8 mg Three Times Daily for Three Years in the Treatment of Early Parkinsonian Patients Not Treated with L-dopa
Phase:	Phase 3
Study Indications or Diseases:	Parkinson Disease
Generic Name:	ropinirole
Trade/Product Name:	requip;requip
Approved Drug Label:	http://www.gsk.com/products.html
Results Summary:	Click here to download result summary.
Citations:	Korczyn AD, Brunt ER, Larsen JP, Nagy Z, Poewe WH, Ruggieri S, for the 053 Study Group. A 3-year randomized trial of ropinirole and bromocriptine in early Parkinson’s disease. Neurology 1999; 53: 364–370 WITH Neurology 1999; 53: 1162 (erratum)